EarningsQ2 2026 Earnings Report
MX:INGR Q2 2026 EPS Results
Actual EPS$51.21
Consensus EPS$49.29
Beat/MissBeat by +$1.93
One Year Ago EPS$52.12
MX:INGR Q2 2026 Revenue Results
Actual Revenue$33.60B
Expected Revenue$33.31B
Beat/MissBeat by +$292.83M
YoY Revenue Growth+0.93%
Earnings Announcement Details
QuarterQ2 2026
Date08/04/2026
TimeBefore Open
Conference CallTuesday, August 4, 2026
MX:INGR Upcoming Earnings
Ingredion's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:INGR Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
Balanced call: clear, continuing strength and momentum in Texture & Healthful Solutions, meaningful strategic progress on the Tate & Lyle acquisition, successful launches and partnerships, and improving operations at Argo provide important positives. Offsetting these are significant operational headwinds (Argo disruptions), notable input-cost pressure (tapioca +40% YTD), Mexico transactional FX impacts, and year-to-date declines in operating income. Management reaffirmed full-year EPS guidance and outlined plans to normalize Argo and capture synergies from M&A, but near-term profitability pressure remains.Company Guidance
Quarterly Net Sales and Top-Line Stability
Q2 net sales of $1.85 billion, up 1% year-over-year; year-to-date net sales approximately $3.6 billion, flat versus prior year. Q3 net sales expected to be up low single digits; full-year net sales guidance reaffirmed as flat to up low single digits.
Texture & Healthful Solutions (T&HS) Outperformance
T&HS net sales up 5% in Q2 with volume growth of 7% (ninth consecutive quarter of volume growth). T&HS operating income up 5% and delivered the second-highest quarterly operating income in segment history. Full-year T&HS net sales expected up mid-single digits and operating income up mid- to high-single digits.
Operational Recovery at Argo
Argo reliability and production improved sequentially during Q2; plant operating at normal production rates across major units at end of June. Margins at the facility experienced significant quarter-over-quarter improvement (management noted ~400 bps improvement) and management expects normalized run rates and margins by year-end.
Strategic M&A Progress — Tate & Lyle
Tate & Lyle shareholders approved the recommended all-cash offer. Transaction expected to add $2.7 billion of revenue, deliver ~$130 million of expected run-rate synergies by 2030, and produce greater than 15% adjusted EPS accretion in the first full calendar year post-acquisition, with a path to under 2.5x net leverage within 18 months of closing.
Innovation and Portfolio Expansion
Launched Ask Ingredion (AI formulation platform); acquired Benicaros (clinically supported immune-health prebiotic); announced strategic partnership with Sanstar to expand pharmaceutical excipient capabilities in India. All Other net sales increased 8% driven by >40% net sales growth in protein fortification (higher-value isolates/specialty proteins).
Capital Allocation and Financial Discipline
Year-to-date cash from operations $123 million (reflecting planned ~$231 million working capital investment); net CapEx $210 million to support reliability and strategic priorities; returned $105 million in dividends and repurchased $14 million of shares YTD; reaffirmed $100 million share repurchase plan for 2026. Full-year cash from operations now expected $700M–$800M and CapEx $450M–$490M.
MX:INGR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed